MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry™ ...

SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...

The MarketWatch News Department was not involved in the creation of this content. LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry(R) Trial (tralokinumab-ldrm) in Patients with Moderate-to ...

The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...

Subcutaneous injection of tralokinumab (Adbry) received approval for adults with moderate-to-severe AD who are candidates for systemic therapy, LEO Pharma announced. The drug is approved in Europe and ...

Indication of Adbry (tralokinumab-ldrm) expanded to include patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical ...

Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022. Tralokinumab is marketed outside of the U.S. under the tradename ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved tralokinumab for the treatment of moderate to severe atopic dermatitis, LEO Pharma ...

Medically reviewed by Patricia Mikula, PharmD Key Takeaways Biologics are used for people with severe eczema when other ...

Interim post-hoc efficacy analysis from ECZTEND, an open-label, 5-year extension trial, showed long-term improvements in extent and severity of atopic dermatitis and itch in a subgroup of adult ...

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...